N-Terminal Pro–B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial
| Autor: | Hugo A. Katus, Allan S. Jaffe, Kay Brune, Eberhard Spanuth, Evangelos Giannitsis, Joachim Moecks |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Clinical Biochemistry Anti-Inflammatory Agents Pilot Projects Risk Assessment Gastroenterology Double-Blind Method Predictive Value of Tests Internal medicine Natriuretic Peptide Brain Osteoarthritis medicine Natriuretic peptide Humans Prospective Studies Myocardial infarction Risk factor Adverse effect Glucocorticoids Stroke Proportional Hazards Models business.industry Anti-Inflammatory Agents Non-Steroidal Biochemistry (medical) Therapeutic effect Middle Aged medicine.disease Brain natriuretic peptide Peptide Fragments Endocrinology Cardiovascular Diseases Heart failure Metalloproteases Female business Biomarkers hormones hormone substitutes and hormone antagonists |
| Zdroj: | Clinical Chemistry. 54:1149-1157 |
| ISSN: | 1530-8561 0009-9147 |
| DOI: | 10.1373/clinchem.2007.097428 |
| Popis: | Background: We investigated whether higher concentrations of N-terminal pro–B-type natriuretic peptide (NT-proBNP) predicts cardiovascular adverse events (CV-AEs) in patients with osteoarthritis treated with antiinflammatory drugs. Methods: NT-proBNP was measured in baseline samples from 433 patients enrolled in a prospective randomized study designed to test the therapeutic effect of a novel metalloproteinase inhibitor. We monitored CV-AEs and retrospectively investigated their relationship to the concomitant use of selective cyclooxygenase-2 inhibitors (coxibs), traditional nonsteroidal antiinflammatory drugs (tNSAIDs), and glucocorticoids. CV-AEs included myocardial infarction, stroke, new or worsening of preexisting arterial hypertension, congestive heart failure, and several less severe CV-AEs. Results: We observed 82 mild to serious CV-AEs during an observational period of 200 days. The risk of such events was 1.95-fold higher in patients who were taking tNSAIDs, glucocorticoids, or coxibs (i.e., any inhibitor) and who had NT-proBNP concentrations ≥100 ng/L than in patients taking any inhibitor who had NT-proBNP values 85% across all treatment groups. Conclusions: NT-proBNP may be a useful marker for anticipating cardiovascular risk associated with the use of antiinflammatory drugs for osteoarthritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|